Hindawi
BioMed Research International
Volume 2021, Article ID 9808613, 2 pages
https://doi.org/10.1155/2021/9808613

Corrigendum

Corrigendum to "Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis"

Wenjing Wang,[1,2,3] **Shubin Niu**,[4] **Luxin Qiao**,[1,2,3] **Feili Wei**,[1,2,3] **Jiming Yin**,[1,2,3] **Shanshan Wang**,[1,2,3] **Yabo Ouyang**,[1,2,3] **and Dexi Chen**[1,2,3]

[1]*Capital Medical University Affiliated Beijing You An Hospital, Beijing 100069, China*
[2]*Beijing Institute of Hepatology, Beijing 100069, China*
[3]*Beijing Precision Medicine and Transformation Engineering Technology Research Center of Hepatitis and Liver Cancer, 100069, China*
[4]*School of Biomedicine, Beijing City University, No. 6 Huanghoudian Road Haidian District, Beijing 100094, China*

Correspondence should be addressed to Dexi Chen; dexichen@ccmu.edu.cn

Received 11 November 2021; Accepted 11 November 2021; Published 22 December 2021

The article titled "Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis" [1] contains a figure duplication in Figures 2 and 3, which was raised on PubPeer [2]. Specifically, Figure 2(c) panel UA + Adr overlaps with Figure 3(c) panel UA + Adr. The authors state that this was due to the incorrect file being selected during the preparation of the figure. The correct Figure 3(c) is as below.



Figure 3

References

[1] W. Wang, S. Niu, L. Qiao et al., "Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis," *BioMed Research International*, vol. 2019, Article ID 8727935, 7 pages, 2019.

[2] E. M. Bik, "Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis," *BioMed Research International*, vol. 2019, no. 1, 2019.